Both the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines suggest identifying genetic alterations, such as IDH1 mutations and fibroblast growth factor receptor 2 (FGFR2) fusion, as pivotal targets for ICC treatment [3, 4]. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.